Best Practice & Research Clinical Haematology

Papers
(The median citation count of Best Practice & Research Clinical Haematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Contemporary and future strategies in polycythemia vera69
The role of randomized controlled trials, registries, observational databases in evaluating new interventions27
Coagulopathy in COVID-19 and anticoagulation clinical trials25
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation25
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL22
Endpoint selection and evaluation in hematology studies22
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)21
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program19
Editorial Board19
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes19
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances19
The presentation of results from studies in clinical haematology16
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms14
Take a spin: Apheresis in the care of adult leukaemia patients14
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma11
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults11
Vaccine-induced immune thrombotic thrombocytopenia11
Targeted cellular therapy for treatment of relapsed or refractory leukemia10
Principles of cost-effectiveness studies and their use in haematology10
Blood coagulation and cancer genes10
Accelerated and blast phase myeloproliferative neoplasms10
Creating a GMP cell processing program: A focus on quality and regulation10
The international cooperative Gaucher group (ICCG) Gaucher registry9
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”9
What should be done and what should be avoided when comparing two treatments?9
Dysregulation of Protein S in COVID-198
Editorial Board8
Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma8
Cancer associated thrombosis in pediatric patients8
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma7
Corrigendum to “Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)” [Best Pract Res Clin Haematol 38 2 2025]7
Addressing symptom burden in myeloproliferative neoplasms7
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration7
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?7
Anti-GM-CSF autoantibodies in myeloid leukemias7
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders7
The role of registries in hematological disorders7
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation7
Thrombosis and bleeding in hematological malignancy6
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies6
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment6
Challenges in anticoagulation for patients with brain tumors6
Handling missing covariate data in clinical studies in haematology6
Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation5
Recent progress in acute leukemia and myelodysplasia5
A reflection on Arnold Caplan, the father of MSC5
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia5
Editorial Board / Aims & Scope5
CAR assembly line: Taking CAR T-cell manufacturing to the next level5
Cytokines in hematopoietic cell transplantation and related cellular therapies5
What is relative survival and what is its role in haematology?4
The most frequent HLA alleles around the world: A fundamental synopsis4
When to use which molecular prognostic scoring system in the management of patients with MDS?4
Preface4
Corrigendum to “Endpoint selection and evaluation in hematology studies” [Best Pract Res Clin Haematol 36 (2023) 101479]4
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care4
Therapeutic initiatives using mesenchymal stem cells and other novel cells in hematology4
Cytogenetics and genomics in CML and other myeloproliferative neoplasms4
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia4
Corrigendum to “Designing and conducting a clinical trial in blood and marrow transplantation” [Best Pract Res Clin Haematol 36 (2023) 101471]4
Preface of special edition “Biostatistics in clinical haematology”3
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma3
CARs for lymphoma3
Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy3
Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation3
Considerations to comprehensive care for the older individual with myelofibrosis3
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents3
Donor lymphocyte infusion in Acute Myeloid Leukemia3
Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults3
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-193
Editorial Board / Aims & Scope3
The best GVHD prophylaxis: Or at least progress towards finding it2
Using real-world evidence in haematology2
Mesenchymal stem cells in hematology: Therapeutic initiatives and future directions2
Editorial Board / Aims & Scope2
Editorial Board2
Cytokines in transplantation tolerance2
Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia2
Myeloproliferative neoplasms in adolescents and young adults2
Editorial Board2
Thromboprophylaxis of cancer patients undergoing systemic therapy in the ambulatory setting2
Consolidation chemotherapy in AML: Are we playing with a full deck of cards?2
Cytokine therapy of acute radiation syndrome2
COVID-19 and antiphospholipid antibodies2
Redox stress in COVID-19: Implications for hematologic disorders2
Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse2
Transplantation algorithm for myelofibrosis in 2022 and beyond2
Natural born Killers: Harnessing NK cells to treat cancer2
Cytogenetics and genomics in pediatric acute lymphoblastic leukaemia2
HLA-DM and HLA-DO interplay for the peptide editing of HLA class II in healthy tissues and leukemia2
Designing and conducting a clinical trial in blood and marrow transplantation2
COVID-19: A hematological perspective2
The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation2
Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders2
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults2
Analyte heterogeneity analysis as a possible potency parameter for MSC2
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry2
Advancing MSC therapy: The next generation of potent mesenchymal stromal cells for systemic autoimmune rheumatic diseases2
0.13308000564575